CALQUENCE (acalabrutinib) capsules, for oral use. Initial U.S. Approval: 2017

Categories: , .

CALQUENCE (acalabrutinib) capsules, for oral use. Initial U.S. Approval: 2017

INDICATIONS AND USAGE
CALQUENCE is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
DOSAGE FORMS & STRENGTHS
Capsules: 100 mg
Manufactured By: AstraZeneca
Prescribing Information URL: Click Here

Access to CALQUENCE ® (acalabrutinib) capsules: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Acalabrutinib, sold under the brand name Calquence, is a medication used to treat a type of non-Hodgkin lymphoma known as mantle cell lymphoma. Specifically it is for people who had previously been treated with another therapy. As of 2019, it was unclear whether it improved outcomes.
Acalabrutinib was approved for medical use in the United States in 2017, and in the European Union in November 2020

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.